New Hope for Cystic Fibrosis Patients as EMA Grants Orphan Drug Status to Investigational Treatment ETD001

Enterprise Therapeutics, a biopharmaceutical company based in Brighton, has received a special designation called ‘orphan medicinal product designation’ from the European Medicines Agency (EMA). This designation is for ETD001, an experimental treatment for cystic fibrosis (CF), a rare and serious lung disease. The company announced this news after ETD001 showed promising results in a phase 2 clinical trial, where it was found to improve lung function by helping to clear mucus from the airways and reducing blockages in the lungs.

The EMA’s Committee for Orphan Medicinal Products (COMP) decided that ETD001 meets the criteria for this special designation because cystic fibrosis is a rare disease and ETD001 could offer significant benefits to patients. The committee also recognized that ETD001 may help people with CF who cannot use current standard treatments called CFTR modulators. These results were supported by data from a phase 2 clinical study called ET-ENAC-03, which showed improvements in lung function for participants.

Orphan drug designation in the European Union provides important incentives for companies developing treatments for rare diseases, including longer-term market protection if the treatment is approved.

Dr. John Ford, CEO of Enterprise Therapeutics, said: ‘This orphan drug designation is a major regulatory achievement for our ETD001 program and our company. The EMA’s decision highlights the ongoing need for new treatment options for people with cystic fibrosis, especially those who cannot benefit from CFTR modulators.’

He also added: ‘We are excited to continue developing ETD001 not only for cystic fibrosis but also for other respiratory diseases that involve mucus congestion.’

Annabella Amatulli, Head of Regulatory Affairs at Enterprise Therapeutics, explained: ‘Our plan for regulatory approval supports our goal to provide better treatment options for people with cystic fibrosis. The EMA’s designation confirms that our scientific approach and the results of our phase 2 clinical trial are strong and promising.’

Cystic fibrosis affects around 100,000 people worldwide. It is a lifelong condition that shortens life expectancy. The disease causes thick, sticky mucus to build up in the lungs, making it difficult to clear out germs. This leads to frequent lung infections, long-term inflammation, and a gradual decline in lung function over time.

Leave a Comment

Scroll to Top